AR040400A1 - Tratamiento de enfermedades mediadas por quimiocinas - Google Patents
Tratamiento de enfermedades mediadas por quimiocinasInfo
- Publication number
- AR040400A1 AR040400A1 AR20030100943A ARP030100943A AR040400A1 AR 040400 A1 AR040400 A1 AR 040400A1 AR 20030100943 A AR20030100943 A AR 20030100943A AR P030100943 A ARP030100943 A AR P030100943A AR 040400 A1 AR040400 A1 AR 040400A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- unsubstituted
- groups
- independently selected
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000001404 mediated effect Effects 0.000 title abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 25
- 125000000217 alkyl group Chemical group 0.000 abstract 17
- 125000001072 heteroaryl group Chemical group 0.000 abstract 13
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000003107 substituted aryl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 7
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 102000019034 Chemokines Human genes 0.000 abstract 2
- 108010012236 Chemokines Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 2
- 238000002483 medication Methods 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- -1 -OH Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 108050006947 CXC Chemokine Proteins 0.000 abstract 1
- 102000019388 CXC chemokine Human genes 0.000 abstract 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 230000008512 biological response Effects 0.000 abstract 1
- 229940111134 coxibs Drugs 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36531402P | 2002-03-18 | 2002-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040400A1 true AR040400A1 (es) | 2005-04-06 |
Family
ID=28454639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030100943A AR040400A1 (es) | 2002-03-18 | 2003-03-18 | Tratamiento de enfermedades mediadas por quimiocinas |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20040053953A1 (https=) |
| EP (1) | EP1485089B1 (https=) |
| JP (1) | JP4733350B2 (https=) |
| CN (1) | CN100444839C (https=) |
| AR (1) | AR040400A1 (https=) |
| AU (1) | AU2003220384B2 (https=) |
| BR (1) | BR0308739A (https=) |
| CA (1) | CA2479126C (https=) |
| MX (1) | MXPA04009127A (https=) |
| NO (1) | NO20044402L (https=) |
| NZ (1) | NZ535314A (https=) |
| TW (2) | TW200808314A (https=) |
| WO (1) | WO2003080053A1 (https=) |
| ZA (1) | ZA200407339B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| CN1289471C (zh) * | 2001-04-16 | 2006-12-13 | 先灵公司 | 作为cxc－趋化因子受体配体的3,4－二取代的环丁烯－1,2－二酮 |
| JP2005505595A (ja) | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| PE20040570A1 (es) | 2002-10-09 | 2004-08-30 | Pharmacopeia Drug Discovery | Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina |
| EP1572029B1 (en) * | 2002-11-07 | 2010-03-24 | Abbott Laboratories | Method of loading beneficial agent to a prosthesis by fluid-jet application |
| US8221495B2 (en) * | 2002-11-07 | 2012-07-17 | Abbott Laboratories | Integration of therapeutic agent into a bioerodible medical device |
| US8524148B2 (en) * | 2002-11-07 | 2013-09-03 | Abbott Laboratories | Method of integrating therapeutic agent into a bioerodible medical device |
| DE602004025458D1 (de) | 2003-04-18 | 2010-03-25 | Schering Corp | SYNTHESE VON 2-HYDROXY-N,N-DIMETHYL-3-ii2-i1(R)-(5-METHYL-2-FURANYL)PROPYL AMINO -3,4-DIOXO-1-CYCLOBUTEN-1-YL AMINO BENZAMID |
| ES2308299T3 (es) | 2003-12-19 | 2008-12-01 | Schering Corp | Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas. |
| TW200530231A (en) * | 2003-12-22 | 2005-09-16 | Schering Corp | Isothiazole dioxides as CXC-and CC-chemokine receptor ligands |
| RU2388756C2 (ru) | 2004-01-30 | 2010-05-10 | Шеринг Корпорейшн | Кристаллические полиморфные формы лиганда схс-хемокинового рецептора |
| DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| CN1997893A (zh) * | 2004-04-16 | 2007-07-11 | 健泰科生物技术公司 | 抗体测定法 |
| CN1984899B (zh) | 2004-05-12 | 2011-07-27 | 先灵公司 | Cxcr1和cxcr2趋化因子拮抗剂 |
| PE20060272A1 (es) * | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| MX2008000367A (es) | 2005-06-29 | 2008-03-07 | Schering Corp | Oxidiazolopirazinas y tiadiazolopirazinas 5,6-di-sustituidas como ligandos de receptor de quimiocina en la que dos cisternas son separadas por un solo aminoacido. |
| EP1912971A2 (en) | 2005-06-29 | 2008-04-23 | Shering Corporation | Di-substituted oxadiazoles as cxc-chemokine receptor ligands |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| KR20090024248A (ko) | 2006-06-12 | 2009-03-06 | 쉐링 코포레이션 | Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법 |
| WO2008005570A1 (en) * | 2006-07-07 | 2008-01-10 | Schering Corporation | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| US8450348B2 (en) * | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| EP2155670B1 (en) | 2007-06-06 | 2012-04-18 | Novartis AG | Anti -inflammatory substituted cyclobutenedione compounds |
| CN101932553A (zh) * | 2007-07-03 | 2010-12-29 | 先灵公司 | 合成1,2-取代的3,4-二氧代-1-环丁烯化合物的方法和中间体 |
| UA103198C2 (en) * | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| WO2010131145A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| FR2961695B1 (fr) * | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
| US20140170112A1 (en) * | 2011-03-12 | 2014-06-19 | Vicus Therapeutics, Llc | Compositions for ameliorating systemic inflammation and methods for making and using them |
| ES2655942T3 (es) | 2011-09-02 | 2018-02-22 | Novartis Ag | Sal de colina de un compuesto anti-inflamatorio de ciclobutenodiona sustituida |
| FR2981934B1 (fr) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| KR101306199B1 (ko) * | 2012-01-31 | 2013-09-09 | 부산대학교 산학협력단 | 포스포리파아제 ｄ 억제제를 유효성분으로 포함하는 골다공증 예방 및 치료용 약학적 조성물 |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| KR20200037857A (ko) | 2017-08-14 | 2020-04-09 | 알러간, 인코포레이티드 | 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도 |
| MY202326A (en) * | 2017-09-14 | 2024-04-24 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
| EP3737366B1 (en) | 2018-01-08 | 2026-02-25 | ChemoCentryx, Inc. | Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2 |
| SG11202101827RA (en) | 2018-09-21 | 2021-04-29 | Pfizer | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors |
| CN112851635B (zh) * | 2019-11-28 | 2022-09-16 | 中国医学科学院药物研究所 | 环状砜类化合物及其制备方法、用途和药物组合物 |
| EP3868368A1 (en) * | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
| CN121693497A (zh) * | 2023-11-03 | 2026-03-17 | 武汉朗来科技发展有限公司 | 作为ccr6拮抗剂的化合物、其药物组合物和用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1531943A (fr) | 1966-07-28 | 1968-07-05 | Huels Chemische Werke Ag | Procédé pour stabiliser des poly-acétals macromoléculaires |
| DE1669798A1 (de) | 1966-07-28 | 1971-08-26 | Huels Chemische Werke Ag | Verfahren zum Stabilisieren markomolekularer Polyacetale |
| CS214745B2 (en) * | 1976-08-28 | 1982-05-28 | Huels Chemische Werke Ag | Shaped and non-shaped products from plastic materials |
| DE2638855C3 (de) | 1976-08-28 | 1980-04-24 | Chemische Werke Huels Ag, 4370 Marl | Verwendung von Quadratsäureamiden als Stabilisierungsmittel für geformte oder nicht geformte Kunststoffe |
| DE3309655A1 (de) | 1983-03-17 | 1984-09-20 | Bayer Ag, 5090 Leverkusen | 1,2,5-thiadiazol-1-oxide und 1,1-dioxide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JPS60255756A (ja) * | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
| US4978665A (en) | 1987-01-20 | 1990-12-18 | Nissan Chemical Industries Ltd. | 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it |
| JPH02256668A (ja) | 1988-12-20 | 1990-10-17 | Nissan Chem Ind Ltd | ピリダジノン誘導体 |
| US5206252A (en) * | 1992-05-08 | 1993-04-27 | American Home Products Corporation | Thiadiazolyl-amino derivatives of benzopyrans and indanes |
| GB9312210D0 (en) | 1993-06-14 | 1993-07-28 | Smithkline Beecham Plc | Chemical compounds |
| US5506252A (en) * | 1993-11-17 | 1996-04-09 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5354763A (en) * | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5466712A (en) | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
| EP0796243B1 (en) | 1994-11-16 | 1999-01-27 | American Home Products Corporation | Diaminocyclobutene-3,4-diones |
| US6300325B1 (en) * | 1997-01-23 | 2001-10-09 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US5840764A (en) * | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| WO1998033763A1 (en) | 1997-01-30 | 1998-08-06 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| AR015425A1 (es) * | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion |
| EP1117633B1 (en) | 1998-10-02 | 2002-09-18 | Neurosearch A/S | Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| AU6111699A (en) | 1998-10-08 | 2000-05-01 | Smithkline Beecham Plc | Novel method and compounds |
| US6376555B1 (en) * | 1998-12-04 | 2002-04-23 | American Home Products Corporation | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers |
| CN1334797A (zh) | 1998-12-14 | 2002-02-06 | 美国家用产品公司 | 抑制经vla－4介导的白细胞粘附的3,4－二氨基－3－环丁烯－1,2－二酮衍生物 |
| DE69927050T2 (de) | 1998-12-16 | 2006-06-29 | Bayer Healthcare Ag | Biphenylverbindungen und biphenyl-analoge als intergrin-antagonisten |
| US6420396B1 (en) * | 1998-12-16 | 2002-07-16 | Beiersdorf Ag | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| US6586446B1 (en) | 1999-10-15 | 2003-07-01 | Bristol-Myers Squibb Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| WO2001064691A1 (en) | 2000-03-01 | 2001-09-07 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| AR033803A1 (es) * | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| JP2003527360A (ja) | 2000-03-14 | 2003-09-16 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体アンタゴニスト |
| MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
| CN1454204A (zh) * | 2000-05-30 | 2003-11-05 | 史密丝克莱恩比彻姆公司 | Il－8受体拮抗剂 |
| JP2004520412A (ja) * | 2001-01-16 | 2004-07-08 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体アンタゴニスト |
| DE60216229T2 (de) * | 2001-01-16 | 2007-10-04 | Smithkline Beecham Corp. | Il-8-rezeptorantagonisten |
| US20030204085A1 (en) * | 2001-02-02 | 2003-10-30 | Taveras Arthur G. | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists |
| WO2002076926A1 (en) * | 2001-02-02 | 2002-10-03 | Schering Corporation | 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists |
| CN1289471C (zh) * | 2001-04-16 | 2006-12-13 | 先灵公司 | 作为cxc－趋化因子受体配体的3,4－二取代的环丁烯－1,2－二酮 |
| US7132445B2 (en) * | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| JP2005505595A (ja) * | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) * | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| JP4836388B2 (ja) | 2002-03-22 | 2011-12-14 | 第一三共株式会社 | ｅＮＯＳ発現に起因する疾患の予防または治療薬 |
| PE20040570A1 (es) * | 2002-10-09 | 2004-08-30 | Pharmacopeia Drug Discovery | Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina |
-
2003
- 2003-03-17 WO PCT/US2003/008287 patent/WO2003080053A1/en not_active Ceased
- 2003-03-17 CA CA2479126A patent/CA2479126C/en not_active Expired - Fee Related
- 2003-03-17 BR BR0308739-5A patent/BR0308739A/pt not_active IP Right Cessation
- 2003-03-17 AU AU2003220384A patent/AU2003220384B2/en not_active Ceased
- 2003-03-17 US US10/390,078 patent/US20040053953A1/en not_active Abandoned
- 2003-03-17 NZ NZ535314A patent/NZ535314A/en not_active IP Right Cessation
- 2003-03-17 MX MXPA04009127A patent/MXPA04009127A/es unknown
- 2003-03-17 EP EP03716685.7A patent/EP1485089B1/en not_active Expired - Lifetime
- 2003-03-17 JP JP2003577881A patent/JP4733350B2/ja not_active Expired - Fee Related
- 2003-03-17 CN CNB038106183A patent/CN100444839C/zh not_active Expired - Fee Related
- 2003-03-18 TW TW096114061A patent/TW200808314A/zh unknown
- 2003-03-18 TW TW092105892A patent/TW200304811A/zh unknown
- 2003-03-18 AR AR20030100943A patent/AR040400A1/es not_active Application Discontinuation
-
2004
- 2004-09-13 ZA ZA200407339A patent/ZA200407339B/en unknown
- 2004-10-15 NO NO20044402A patent/NO20044402L/no not_active Application Discontinuation
-
2007
- 2007-02-14 US US11/705,929 patent/US7960433B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003080053A1 (en) | 2003-10-02 |
| ZA200407339B (en) | 2005-10-06 |
| NO20044402L (no) | 2004-12-17 |
| US20040053953A1 (en) | 2004-03-18 |
| MXPA04009127A (es) | 2005-01-25 |
| US20070155756A1 (en) | 2007-07-05 |
| JP4733350B2 (ja) | 2011-07-27 |
| NZ535314A (en) | 2007-08-31 |
| AU2003220384B2 (en) | 2007-05-10 |
| US7960433B2 (en) | 2011-06-14 |
| CN1652779A (zh) | 2005-08-10 |
| TW200808314A (en) | 2008-02-16 |
| CN100444839C (zh) | 2008-12-24 |
| CA2479126C (en) | 2011-11-15 |
| JP2005533005A (ja) | 2005-11-04 |
| EP1485089B1 (en) | 2013-04-17 |
| TW200304811A (en) | 2003-10-16 |
| AU2003220384A1 (en) | 2003-10-08 |
| EP1485089A1 (en) | 2004-12-15 |
| CA2479126A1 (en) | 2003-10-02 |
| BR0308739A (pt) | 2005-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040400A1 (es) | Tratamiento de enfermedades mediadas por quimiocinas | |
| AR035825A1 (es) | Ciclobuten-1,2-dionas 3,4-di-sustituidas y sus sales como ligandos del receptor de cxc-quimiocina, composiciones farmaceuticas y el uso de las mismas para la fabricacion de un medicamento | |
| AR043052A1 (es) | Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| AR036103A1 (es) | Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento | |
| AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
| TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
| AR033594A1 (es) | Un compuesto derivado de 3-aroilindol, su utilizacion, procedimientos para prepararlo, una composicion farmaceutica que lo contiene, un medicamento constituido por dicho compuesto, y compuestos intermediarios | |
| AR054799A1 (es) | Derivados de oxindol | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| EA200700099A1 (ru) | Производные пиридина | |
| AR044909A1 (es) | Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia | |
| AR044036A1 (es) | Compuestos de pirazolopirimidinas y pirazolopiridinas como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos | |
| AR035371A1 (es) | Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
| CY1108714T1 (el) | Ανταγωνιστες υποδοχεα cgrp | |
| AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
| AR061114A1 (es) | Arilimidazolonas y ariltriazolonas sustituidas asi como su uso | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| HUP0302891A2 (hu) | PDE4 izoenzimek inhibitoraiként alkalmazható éterszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| AR046791A1 (es) | Tiadiazoles como ligandos del receptor cxc y cc-quimioquina; composiciones farmaceuticas que los contienen como principio activo y su empleo en la preparacion de medicamentos. | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |